Introduction: The Future of Haemophilia A Treatment
When it comes to rare blood diseases, the introduction of Emicizumab, a bispecific monoclonal antibody, has been a significant milestone in the
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.